The impact of sustained and intermittent docetaxel chemotherapy regimens on cognition and neural morphology in healthy mice
- 389 Downloads
A subset of cancer survivors demonstrates impairments in cognition long after chemotherapy completion. At present, it is unclear whether these changes are due to direct neurotoxic effects of chemotherapy.
This study examined the impact of variable docetaxel (DTX) chemotherapy dosing on brain DTX exposure via analyses of neural morphology and changes in cognition.
Male CD-1 mice were treated with DTX either intermittently (8 mg/kg i.p. weekly) or via a sustained delivery system (DTX-PoLigel), which continuously releases DTX. Both groups received total DTX doses of 32 mg/kg. Mice were assessed on the novel object recognition (NOR) task and the Morris water maze (MWM) shortly after treatment.
Post-treatment behavioral testing demonstrated impaired NOR in mice treated with either dosing schedule relative to controls. No differences were observed between groups in MWM training and initial testing, though control mice performed better than chance while DTX-treated mice did not. Appreciable amounts of DTX were found in the brain after both treatment regimens. DTX treatment did not significantly increase levels of apoptosis within the CNS. However, some elevation in neural autophagy was observed following DTX treatment. Analysis of astrocytic activation demonstrated that intermittent DTX treatment resulted in an elevation of GFAP-positive astrocytes for 48 h after administration. Sustained chemotherapy demonstrated prolonged but lower levels of astrocyte activation over 9 days following implantation.
DTX treatment induced cognitive impairment shortly after treatment. Further, these findings suggest an association between DTX dosing, neurotoxicity, and cognitive effects.
KeywordsChemobrain Chemotherapy Cognition Memory Docetaxel Autophagy Mice
Central nervous system
Glial fibrillary acidic protein
High-performance liquid chromatography tandem mass spectrometry
Morris water maze
Novel object recognition
The research presented in this paper was funded by the Ontario Division of the Canadian Cancer Society (CCS grant # 019283 held by MPM and CA). Ms. Fardell would like to acknowledge the RSA funding from the Cancer Institute NSW, Australia, and the Campbell Perry International Travel Scholarship, School of Psychology, University of Sydney.
- Blackburn D, Sargsyan S, Monk PN, Shaw PJ (2009). Astrocyte function and role in motor neuron disease: a future therapeutic target? Glia 57(12):1251–1264Google Scholar
- Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23:3686–96PubMedCrossRefGoogle Scholar
- Persohn E, Canta A, Schoepfer S, Traebert M, Mueller L, Gilardini A, Galbiati S, Nicolini G, Scuteri A, Lanzani F, Giussani G, Cavaletti G (2005) Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 41:1460–6PubMedCrossRefGoogle Scholar
- Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, Waddell K, Petersen L, Phelps ME, Ganz PA (2007) Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat 103:303–11PubMedCrossRefGoogle Scholar
- Zahedi P, Stewart J, De Souza R, Piquette-Miller M, Allen C (2011) An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels. J Control Release 158:379–85PubMedCrossRefGoogle Scholar